Athira Pharma, Inc. (NASDAQ:LONA) Stock Short Interest Report for October

Athira Pharma, Inc. (NASDAQ:LONA) was the target of a large increase in short interest during the month of October. As of October 15th, there was short interest totaling 87,344 shares, an increase of 355.7% from the September 30th total of 19,166 shares. Approximately 1.3% of the company’s shares are short sold. Based on an average trading volume of 726,433 shares, the short-interest ratio is currently 0.1 days.

Athira Pharma Price Performance

Shares of NASDAQ:LONA traded up $0.04 during trading on Thursday, hitting $5.00. 145,711 shares of the company’s stock were exchanged, compared to its average volume of 96,943. The business’s 50-day simple moving average is $6.17 and its 200 day simple moving average is $7.59. Athira Pharma has a 52-week low of $2.21 and a 52-week high of $14.21. The company has a market cap of $46.97 million, a price-to-earnings ratio of -1.19 and a beta of 2.11.

Athira Pharma (NASDAQ:LONA) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.20). On average, sell-side analysts anticipate that Athira Pharma will post -2.67 EPS for the current fiscal year.

Analysts Set New Price Targets

LONA has been the topic of several research reports. Citizens Jmp dropped their price objective on shares of Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating on the stock in a research note on Monday, August 17th. Wall Street Zen upgraded Athira Pharma to a “hold” rating in a research note on Saturday, October 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Athira Pharma in a research report on Friday, August 7th. Finally, Mizuho decreased their target price on Athira Pharma from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Wednesday, August 19th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Athira Pharma currently has a consensus rating of “Moderate Buy” and an average price target of $17.33.

About Athira Pharma

Athira Pharma is a clinical-stage biotechnology company focused on developing regenerative therapies for neurodegenerative diseases. Its research has centered on treatments intended to activate the hepatocyte growth factor pathway, which may support neuronal health, repair, and regeneration.

The company’s lead investigational product is fosgonimeton, formerly known as ATH-1017, an intravenous therapy developed for potential use in Alzheimer’s disease and other neurodegenerative conditions.